Skip to Content
 
Laura Williams Goff

Laura Williams Goff, M.D.

Assistant Professor of Medicine (Hematology/Oncology)
Associate Director, Hematology/Oncology Fellowship Program

Profile

Dr. Goff is a medical oncologist who specializes in gastrointestinal cancers with an emphasis on tumors of the liver and biliary tract. Dr. Goff received her medical degree from the University of Texas Health Science Center in San Antonio. She went on to complete a residency in Internal Medicine at the University of Texas Southwestern Medical Center at Dallas and then moved to Vanderbilt University for fellowship training in Hematology and Oncology. She joined the faculty in the GI Oncology program at Vanderbilt in 2007. Dr. Goff is interested in developing the use of new therapeutics in gastrointestinal malignancies through clinical trials and translational research.

Education
  • Duke University, B.S., Chemistry, 1993-1997
  • University of Texas Medical School at San Antonio, M.D., 1997-2001
  • University of Texas Southwestern, House Officer, 2001-2004
  • Fellow, Hematology/Oncology, Vanderbilt University Medical Center, 2004-2007
  • Vanderbilt University, Master of Science in Clinical Investigation, 2006-2008
Publications
  • Chan E, Goff LW, Cardin DB, Ancell K, Smith SJ, Whisenant JG, Ye F, Berlin JD. Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Invest New Drugs [print-electronic]. 2017 Aug; 35(4): 491-8. PMID: 28353122, PII: 10.1007/s10637-017-0458-8, DOI: 10.1007/s10637-017-0458-8, ISSN: 1573-0646.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/28353122.
  • Cardin DB, Thota R, Goff LW, Berlin JD, Jones CM, Ayers GD, Whisenant JG, Chan E. A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Am. J. Clin. Oncol [print-electronic]. 2017 Mar 3/15/2017; PMID: 28301350, DOI: 10.1097/COC.0000000000000377, ISSN: 1537-453X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/28301350.
  • Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs [print-electronic]. 2017 Feb; 35(1): 95-104. PMID: 27853997, PMCID: PMC5306261, PII: 10.1007/s10637-016-0406-z, DOI: 10.1007/s10637-016-0406-z, ISSN: 1573-0646.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27853997.
  • Pauff JM, Goff LW. Current Progress in Immunotherapy for the Treatment of Biliary Cancers. J Gastrointest Cancer. 2016 Dec; 47(4): 351-7. PMID: 27538880, PII: 10.1007/s12029-016-9867-8, DOI: 10.1007/s12029-016-9867-8, ISSN: 1941-6636.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27538880.
  • Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, Wang E, Borghaei H. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clin. Cancer Res [print-electronic]. 2016 May 5/1/2016; 22(9): 2146-54. PMID: 26655846, PII: 1078-0432.CCR-15-1622, DOI: 10.1158/1078-0432.CCR-15-1622, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26655846.
  • Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD, Parikh A, Abramson RG, Yankeelov TE, Hiebert S, Merchant N, Bhaskara S, Chakravarthy AB. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiother Oncol [print-electronic]. 2016 May; 119(2): 312-8. PMID: 27106554, PMCID: PMC4961249, PII: S0167-8140(16)31047-7, DOI: 10.1016/j.radonc.2016.04.013, ISSN: 1879-0887.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27106554.
  • Katsha A, Belkhiri A, Goff L, El-Rifai W. Aurora kinase A in gastrointestinal cancers: time to target. Mol. Cancer. 2015 May 5/20/2015; 14: 106. PMID: 25987188, PMCID: PMC4436812, PII: 10.1186/s12943-015-0375-4, DOI: 10.1186/s12943-015-0375-4, ISSN: 1476-4598.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25987188.
  • Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans TR. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin. Cancer Res [print-electronic]. 2015 Feb 2/15/2015; 21(4): 701-11. PMID: 25212606, PII: 1078-0432.CCR-14-0303, DOI: 10.1158/1078-0432.CCR-14-0303, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25212606.
  • Puzanov I, Sosman J, Santoro A, Saif MW, Goff L, Dy GK, Zucali P, Means-Powell JA, Ma WW, Simonelli M, Martell R, Chai F, Lamar M, Savage RE, Schwartz B, Adjei AA. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs [print-electronic]. 2015 Feb; 33(1): 159-68. PMID: 25294187, PMCID: PMC4295023, DOI: 10.1007/s10637-014-0167-5, ISSN: 1573-0646.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25294187.
  • Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Med [print-electronic]. 2014 Jun; 3(3): 572-9. PMID: 24574334, PMCID: PMC4101748, DOI: 10.1002/cam4.208, ISSN: 2045-7634.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24574334.
  • Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24797823.
  • Shaikh F, Goff LW. Decoding hepatocellular carcinoma: the promise of microRNAs. Hepatobiliary Surg Nutr. 2014 Apr; 3(2): 93-4. PMID: 24812602, PMCID: PMC3999426, PII: hbsn-03-02-093, DOI: 10.3978/j.issn.2304-3881.2014.02.08, ISSN: 2304-3881.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24812602.
  • Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC. Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. PLoS ONE. 2014; 9(9): e107424. PMID: 25232828, PMCID: PMC4169411, PII: PONE-D-14-22736, DOI: 10.1371/journal.pone.0107424, ISSN: 1932-6203.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25232828.
  • Ciombor KK, Goff LW. Current therapy and future directions in biliary tract malignancies. Curr Treat Options Oncol. 2013 Sep; 14(3): 337-49. PMID: 23686724, PMCID: PMC3769474, DOI: 10.1007/s11864-013-0237-5, ISSN: 1534-6277.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23686724.
  • Infante JR, Bendell JC, Goff LW, Jones SF, Chan E, Sudo T, Burris HA, Berlin JD. Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer. Eur. J. Cancer [print-electronic]. 2013 Apr; 49(6): 1169-75. PMID: 23294608, PII: S0959-8049(12)00929-X, DOI: 10.1016/j.ejca.2012.11.033, ISSN: 1879-0852.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23294608.
  • Ciombor KK, Goff LW. Advances in the management of biliary tract cancers. Clin Adv Hematol Oncol. 2013 Jan; 11(1): 28-34. PMID: 23416860, PMCID: PMC3713630, ISSN: 1543-0790.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23416860.
  • Venepalli NK, Goff L. Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. Int J Hepatol [print-electronic]. 2013; 2013: 341636. PMID: 23606971, PMCID: PMC3626399, DOI: 10.1155/2013/341636, ISSN: 2090-3448.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23606971.
  • Chi M, Mikhitarian K, Shi C, Goff LW. Management of combined hepatocellular-cholangiocarcinoma: a case report and literature review. Gastrointest Cancer Res. 2012 Nov; 5(6): 199-202. PMID: 23293701, PMCID: PMC3533848, ISSN: 1934-7820.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23293701.
  • Goff LW, Benson AB, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Invest New Drugs [print-electronic]. 2012 Feb; 30(1): 290-8. PMID: 20857171, DOI: 10.1007/s10637-010-9528-x, ISSN: 1573-0646.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20857171.
  • Goff LW, Berlin JD. Advanced biliary tract cancers. Am Soc Clin Oncol Educ Book. 2012; 281-2. PMID: 24451749, PII: 203, DOI: 10.14694/EdBook_AM.2012.32.281, ISSN: 1548-8748.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24451749.
  • Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J. Clin. Oncol [print-electronic]. 2011 Jun 6/10/2011; 29(17): 2357-63. PMID: 21519026, PMCID: PMC3107751, PII: JCO.2010.33.9473, DOI: 10.1200/JCO.2010.33.9473, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21519026.
  • O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol [print-electronic]. 2011 Jun 6/10/2011; 29(17): 2350-6. PMID: 21519015, PMCID: PMC3107750, PII: JCO.2010.33.9432, DOI: 10.1200/JCO.2010.33.9432, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21519015.
  • Mukherjee K, Chakravarthy AB, Goff LW, El-Rifai W. Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy. Dig. Dis. Sci [print-electronic]. 2010 Dec; 55(12): 3304-14. PMID: 20300841, PMCID: PMC2890301, DOI: 10.1007/s10620-010-1187-4, ISSN: 1573-2568.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20300841.
  • Ewing GP, Goff LW. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer. 2010 Oct; 9(4): 219-23. PMID: 20920993, PII: S1533-0028(11)70005-6, DOI: 10.3816/CCC.2010.n.032, ISSN: 1938-0674.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20920993.
  • Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors--rising stars in cancer therapeutics?. Mol. Cancer Ther [print-electronic]. 2010 Feb; 9(2): 268-78. PMID: 20124450, PMCID: PMC2820587, PII: 1535-7163.MCT-09-0765, DOI: 10.1158/1535-7163.MCT-09-0765, ISSN: 1538-8514.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20124450.
  • Pohlmann PR, Mernaugh RL, Goff LW. Chemotherapy and immunotherapy in metastatic colorectal cancer [letter]. N. Engl. J. Med. 2009 May 5/14/2009; 360(20): 2134; author reply 2135-6. PMID: 19439750, PII: 360/20/2134, DOI: 10.1056/NEJMc090489, ISSN: 1533-4406.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19439750.
  • Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009 Apr; 7(4): 350-91. PMID: 19406039, PMCID: PMC4461147.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19406039.
  • Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD. A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Am. J. Clin. Oncol. 2008 Oct; 31(5): 413-6. PMID: 18838875, PII: 00000421-200810000-00002, DOI: 10.1097/COC.0b013e318168ef2a, ISSN: 1537-453X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18838875.